Skip to main content

PhaseBio Pharmaceuticals Inc

PHASDelisted Dec 21, 2022
Industry
Pharmaceutical Preparations
SEC CIK
0001169245

PhaseBio Pharmaceuticals Inc was delisted on Dec 21, 2022; its insiders filed their last Form 4 on May 19, 2023; 39 institutions reported holding it in 13F filings for Q3 2022, worth $3.90M in total; no superinvestor held it.

Q4 2021 vs. Q3 2021

How the institutions holding PhaseBio Pharmaceuticals Inc changed between Q3 2021 and Q4 2021.

All holders in Q4 2021All holders in Q3 2021

13F holders of PHAS: Q3 2021 compared with Q4 2021
MeasureQ3 2021Q4 2021Change
Holders6252−10
Shares30.8M28.2M−2.67M (−8.7%)
Value$95.9M$73.5M−$22.4M (−23.4%)

New holders (10)

Institutions that held PhaseBio Pharmaceuticals Inc at the end of Q4 2021 but not at the end of Q3 2021.

Institutions new to PHAS in Q4 2021
InstitutionSharesValue% of portfolio
ExodusPoint Capital Management, LP394,211$1.03M0.01%
Spire Wealth Management253,723$662.0K0.01%
New Legacy Group, LLC240,575$628.0K0.12%
Northeast Financial Consultants Inc37,760$99.0K0.01%
Two Sigma Advisers, LP30,400$79.0K0.00%
IPG Investment Advisors LLC28,900$76.0K0.01%
Raymond James & Associates15,500$40.0K0.00%
Sargent Investment Group, LLC11,675$30.0K0.01%
Toronto Dominion Bank5,050$13.0K0.00%
TD Waterhouse Canada Inc.850$2.76K0.00%

Sold out (20)

Institutions that held PhaseBio Pharmaceuticals Inc at the end of Q3 2021 and filed for Q4 2021 without it.